Here’s What Lifted Thermo Fisher Scientific (TMO) in Q3

Bristol Gate Capital Partners, an investment management company, published its Q3 2025 investor letter for the “US Equity Strategy”. A copy of the letter can be downloaded here. The strategy underperformed the benchmark, the S&P 500® Total Return Index, this quarter, but still surpassed the index in dividend growth. The underperformance was due to a lack of significant exposure to the AI/TMT sector or the Value sector, which provides advantages stemming from the Federal Reserve’s rate cut. The portfolio returned 15% dividend growth over the trailing 12 months, driven by the strong underlying fundamentals. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Bristol Gate US Equity Strategy highlighted stocks such as Thermo Fisher Scientific Inc. (NYSE:TMO). Thermo Fisher Scientific Inc. (NYSE:TMO) offers life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services. The one-month return of Thermo Fisher Scientific Inc. (NYSE:TMO) was 0.53%, and its shares gained 12.15% of their value over the last 52 weeks. On December 30, 2025, Thermo Fisher Scientific Inc. (NYSE:TMO) stock closed at $583.45 per share, with a market capitalization of $219.207 billion.

Bristol Gate US Equity Strategy stated the following regarding Thermo Fisher Scientific Inc. (NYSE:TMO) in its third quarter 2025 investor letter:

“Thermo Fisher Scientific Inc. (NYSE:TMO) saw their stock price move 9% higher after releasing positive earnings on July 23. The company reported Q2 2025 revenue of $10.85B versus the consensus analyst estimate of $10.68B. Earnings per share also came in higher than estimates at $5.36/share versus $5.22/share. Organic growth of 2% during the quarter and maintaining its long term guidance was enough to overcome very poor sentiment and get the stock moving.”

BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View

Thermo Fisher Scientific Inc. (NYSE:TMO) is in 26th position on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 121 hedge fund portfolios held Thermo Fisher Scientific Inc. (NYSE:TMO) at the end of the third quarter, up from 117 in the previous quarter. While we acknowledge the risk and potential of Thermo Fisher Scientific Inc. (NYSE:TMO) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Thermo Fisher Scientific Inc. (NYSE:TMO) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Thermo Fisher Scientific Inc. (NYSE:TMO) and shared the list of best dividend stocks. Artisan Value Fund initiated a position in Thermo Fisher Scientific Inc. (NYSE:TMO) during Q3 2025. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.